| __timestamp | Celldex Therapeutics, Inc. | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20622000 | 1499100000 |
| Thursday, January 1, 2015 | 33837000 | 1923500000 |
| Friday, January 1, 2016 | 35979000 | 2351400000 |
| Sunday, January 1, 2017 | 25003000 | 2564000000 |
| Monday, January 1, 2018 | 19269000 | 2397300000 |
| Tuesday, January 1, 2019 | 15426000 | 2503400000 |
| Wednesday, January 1, 2020 | 14456000 | 3344600000 |
| Friday, January 1, 2021 | 20488000 | 4529200000 |
| Saturday, January 1, 2022 | 27195000 | 4179100000 |
| Sunday, January 1, 2023 | 30914000 | 4650100000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical landscape, understanding the financial health of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Viatris Inc. and Celldex Therapeutics, Inc. from 2014 to 2023. Over this period, Viatris Inc. consistently reported significantly higher SG&A expenses, peaking at approximately $4.65 billion in 2023, a staggering 15% increase from 2020. In contrast, Celldex Therapeutics, Inc. maintained a more modest expenditure, with a peak of around $36 million in 2016. This disparity highlights the scale and operational differences between the two companies. While Viatris's expenses reflect its expansive operations, Celldex's leaner approach may indicate a focus on niche markets. As the industry continues to grow, these financial strategies will play a pivotal role in shaping their futures.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Celldex Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Halozyme Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Viatris Inc. and Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Ionis Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc. Trends and Insights
Bausch Health Companies Inc. and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
MannKind Corporation and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Travere Therapeutics, Inc. and Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. or Evotec SE: Who Manages SG&A Costs Better?